Tauns Laboratories, Inc.

As of December 31, 2025, Tauns Laboratories, Inc. carries a market capitalization of 54.16B, placing it among publicly traded companies globally. Its enterprise value stands at 72.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tauns Laboratories, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of December 31, 2025, Tauns Laboratories, Inc. has 106.40M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Tauns Laboratories, Inc. maintains a current ratio of 1.44, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Tauns Laboratories, Inc.'s stock has declined approximately 10.36% over the past 52 weeks. The 50-day moving average sits at 506.80, while the 200-day moving average is 505.46.

As of December 31, 2025, Tauns Laboratories, Inc. holds 4.26B in cash and equivalents against 22.15B in total debt, resulting in a net debt position of 17.90B. Total book value stands at 17.41B, with working capital of 5.76B providing operational flexibility.